[1] Chen DS, Irving BA, Hodi FS.Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1[J]. Clin Cancer Res,2012,18(24):6580-6587.
[2] Patel SP, Kurzrock R.PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy[J]. Mol Cancer Ther,2015,14(4):847-856.
[3] Reck M, Rodríguez-Abreu D, Robinson AG, et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med,2016,375(19):1823-1833.
[4] Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project[J]. J Thorac Oncol,2017,12(2):208-222.
[5] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science.2015 Apr 3;348(6230):124-128.
[6] Goodman AM, Kato S, Bazhenova L, et al.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers[J]. Mol Cancer Ther,2017,16(11):2598-2608.
[7] Carbone DP, Reck M, Paz-Ares L, et al.First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med,2017,376(25):2415-2426.
[8] Antonia SJ, López-Martin JA, Bendell J, et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol,2016,17(7):883-895.
[9] Hellmann MD, Ciuleanu TE, Pluzanski A, et al.Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J]. N Engl J Med,2018,378(22):2093-2104.
[10] Ilson DH.Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer[J]. NEJM Journal Watch,2017.
[11] Sclafani F.PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer[J]. Lancet Oncol,2017,18(9):1141-1142.
[12] Quiroga D, Lyerly HK, Morse MA.Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer[J]. Curr Treat Options Oncol,2016,17(8):41.
[13] Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol,2017,18(9):1182-1191.
[14] Mehnert JM, Panda A, Zhong H, et al.Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer[J]. J Clin Invest,2016,126(6):2334-2340.
[15] Dong ZY, Zhong WZ, Zhang XC, et al.Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma[J]. Clin Cancer Res,2017,23(12):3012-3024.
[16] Gainor JF, Shaw AT, Sequist LV, et al.EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis[J]. Clin Cancer Res,2016,22(18):4585-4593.
[17] Shin DS, Zaretsky JM, Escuin-Ordinas H, et al.Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations[J]. Cancer Discov,2017,7(2):188-201.
[18] Wezel F, Vallo S, Roghmann F, et al.Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?[J]. Transl Androl Urol,2017,6(6):1067-1080.
[19] Kato S, Goodman A, Walavalkar V, et al.Hyperprogressors after Immunotherapy: Analysis of Genomic Altera-tions Associated with Accelerated Growth Rate[J]. Clin Cancer Res,2017,23(15):4242-4250.
[20] Sivan A, Corrales L, Hubert N, et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science,2015,350(6264):1084-1089.
[21] Routy B, Le Chatelier E, Derosa L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91-97.
